CN101669930A - Medicament capable of radically treating cardiovascular and cerebrovascular diseases and hypertensions - Google Patents
Medicament capable of radically treating cardiovascular and cerebrovascular diseases and hypertensions Download PDFInfo
- Publication number
- CN101669930A CN101669930A CN200910067571A CN200910067571A CN101669930A CN 101669930 A CN101669930 A CN 101669930A CN 200910067571 A CN200910067571 A CN 200910067571A CN 200910067571 A CN200910067571 A CN 200910067571A CN 101669930 A CN101669930 A CN 101669930A
- Authority
- CN
- China
- Prior art keywords
- linolenic acid
- acid
- blood
- medicament
- alpha
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention relates to a medicament capable of radically treating cardiovascular and cerebrovascular diseases and hypertensions, in particular to a medicament combination. The medicament is preparedby mixing 40-60 parts by weight of alpha-linolenic acid, 0.6-1.4 parts by weight of gamma-linolenic acid and 0.2-1.2 parts by weight of arachidonic acid. The medicament can be prepared by mixing perilla oil, evening primrose oil and the arachidonic acid, and the dosage form can be oral liquid or a capsule. The medicament can effectively treat cardiovascular and cerebrovascular diseases and hypertensions without relapse after healing and effectively prolong the life of people.
Description
Technical field:
The present invention relates to a kind of medicine, relate in particular to a kind of drug regimen.
Background technology:
Cardiovascular and cerebrovascular disease and hypertension are the formidable enemies of human health, and present Therapeutic Method generally adopts the oral or injection of Western medicine, can only play mitigation to the state of an illness, does not also find the effective ways of this class disease of radical cure.
Summary of the invention:
The object of the present invention is to provide and a kind ofly can effect a radical cure cardiovascular and cerebrovascular disease and hypertensive medicine.
The technical scheme that the present invention deals with problems is to adopt a-linolenic acid, r-linolenic acid and arachidonic acid to be mixed and made into, and by weight calculating, the a-linolenic acid is 40-60; The r-linolenic acid is 0.6-1.4; Arachidonic acid is 0.2-1.2.
The preferential weight ratio of the various crude drug of medicine of the present invention is 45-55 for the a-linolenic acid; The r-linolenic acid is 0.8-1.2; Arachidonic acid is 0.4-1.0.
The optimum weight ratio of the various crude drug of medicine of the present invention is 50 for the a-linolenic acid; The r-linolenic acid is 1; Arachidonic acid is 0.4.
The a-linolenic acid of this medicine derives from Fructus Perillae oil, and the r-linolenic acid derives from Radix Oenotherae erythrosepalae oil, and arachidonic acid derives from the biofermentation preparation.Through test, Fructus Perillae oil contains a-linolenic acid 60-65%, and Radix Oenotherae erythrosepalae oil contains r-linolenic acid 9-11%.
Medicine of the present invention can be mixed and made into by Fructus Perillae oil, Radix Oenotherae erythrosepalae oil and arachidonic acid.Dosage form can be oral liquid or capsule.
Linolenic function of a-and effect:
Natural a-linolenic acid is present in Fructus Perillae, and Semen Lini is in the walnut oil.
1, alpha-linolenic acid is to hypertensive effect: alpha-linolenic acid through desaturation, forms prostaglandin PGI3 in human body, has synthetic and other material of the angiotensin of inhibition and changes into the effect of angiotensin, and directly reduce antiotasis and dredging vascellum.Can quicken the running of cholesterol and triglyceride drains, prevent their depositions in vivo and blood vessel wall, dissolve and removes fine and close hard material on the blood vessel wall, the cicatrix of reparation blood vessel wall, prevent that deposit from forming once more, make the smooth flexible and permeability of blood vessel, reduce vascular resistance, vasodilator, and inhibition platelet aggregation, dilute blood viscosity fundamentally brings high blood pressure down, the blood pressure regulation balance.
2, alpha-linolenic acid and fatty liver
Liver is one of organ that utilizes free fatty acid in the blood circulation, and the concentration of fatty acid is high more, and the amount of liver picked-up just the more.Satisfied fatty acid is converted into triglyceride through multiple metabolic pathway in liver, and then mixes lipoprotein and go so that be secreted in the blood circulation.Long-term absorption satisfied fatty acid makes the synthetic formation ability that has surpassed lipoprotein of triglyceride in the liver, the triglyceride that does not have lipoprotein to help to shift will accumulate with the form of lipid droplet in liver, thereby cause fatty liver, further then change liver cirrhosis into.
The mechanism and the hyperlipemia of fatty liver are basic identical, and it enters the drainage that can quicken satisfied fatty acid behind the human liver, suppress the synthetic of triglyceride, strengthen the lipoprotein synthesis capability, prevent that too much triglyceride from accumulating in liver and cause fatty liver.
3, alpha-linolenic acid is to obesity, the effect of hyperlipidemia and fatty liver
Satisfied fatty acid can metabolism generate triglyceride after entering human body, is transported to organ by blood and uses.When the amount of triglyceride needed greater than body, remaining triglyceride will change lipid droplet into and accumulate down at some position, in the course of time, and the disease of causeing fat, fatty liver, hyperlipemia.
Simultaneously satisfied fatty acid can promote the synthetic of low density lipoprotein, LDL in the human body, cholesterol Shen in the blood is amassed in blood vessel wall cause luminal stenosis, the tube wall sclerosis.
Alpha-linolenic acid can promote the synthetic to stop low density lipoprotein, LDL to enter in the arterial wall smooth muscle cell of high density lipoprotein, and low-density and the very low density lipoprotein (VLDL) of Shen Dian in tunica intima and the blood vessel become solubility, carrying out metabolism by blood transport to liver decomposes, the absorption of regulating lipid is with synthetic, the recruitment of cholesterol or triglyceride and be combined into ester in the control blood with cholesterol, with its running, metabolism and drainage.Alpha-linolenic acid is by the triglyceride in the minimizing very low density lipoprotein (VLDL) and the biosynthesis of apolipoprotein, increasing steroid drains, reduce the HMA-COA reductase activity, rising cholesterol fat acyltransferase activity, reach cholesterol reducing, reducing fat reaches the function of fat-reducing, and strengthens the formation ability of lipoprotein, prevents that too much triglyceride from gathering in liver and cause fatty liver.
4, the a-linolenic acid is to the effect of thrombus disease.
Thrombus disease and hyperlipidemia, hypertension, hyperglycemia three is closely related.The fatty spew that cholesterol, triglyceride form is deposited on and produces atherosclerotic plaque in the arterial blood tube wall, vessel lumen is narrowed down gradually even blocks, causes that the tissue of institute's blood supply or organ ischemia or infraction harden.Most blood viscosity height of the people of hyperlipidemia in addition, to establish a capital be hyperlipidemia and the people of high blood viscosity differs.Under the high blood viscosity state, the erythrocyte deformation force descends, oxygen carrying capacity descends, and platelet aggregation can strengthen, and easily forms circular type's [, thromboembolism blood capillary, thereby the thromboembolism of initiation major blood vessel.High blood viscosity is the root of thrombosis, apoplexy still not, also can cause each internal organs oxygen supply deficiency, and after one's own heart the human body blood supply insufficiency can develop into angina pectoris, coronary heart disease; Cerebral blood supply insufficiency regular meeting dizziness headache, hypomnesis may develop into brain atrophy, alzheimer disease etc. and increase the weight of diabetes trunk and microvascular complication, so high blood viscosity is a main root that jeopardizes health of heart and brain.
Alpha-linolenic acid generates the antithrombase element by liver metabolism, suppresses platelet aggregation and evacuates oneself accumulative platelet, dissolves sludged blood, the mediation blood flow, and balancing blood pressure prevents blood vessel embolism or breaks.Alpha-linolenic acid can also promote the synthetic of high density lipoprotein, remove the fatty spew in the arteries, remove a hidden danger, replenish vascular nutrition, recover blood vessel elasticity, repair the cicatrix on the blood vessel wall, the recovery blood vessel wall is smooth, cholesterol in the anti-hemostasis adheres to the formation thrombosis once more and waits the generation that prevents thrombotic disease, reduces ventricular fibrillation, reduces the danger of sudden cardiac arrest and sudden cardiac death.
5, alpha-linolenic acid is to the effect of liver
1. in the infection hepatitis virus be, because virus attack hepatocyte, in intracellular propagation, destroyed a large amount of hepatocyte, and alpha-linolenic acid is the key component that cell membrane constitutes, be of value to hepatocellular regeneration, and improved the antiviral property of liver plasma membrane, the protection hepatocyte is exempted the infringement of virus.
2. alpha-linolenic acid has anti peroxidation of lipid, remove the effect of free radical, prolong the half-life of peroxide dismutase, suppress lipid peroxidation, reduce lipid peroxide and generate, improve the humoral immunization of human body. promote the generation of immunoglobulin, increase production of antibodies and secretion, interferon increases, the more effective virus of killing; Weaken the spleen natural killer cell simultaneously and, strengthen cellular immunization, increase the phagocytic activity of mononuclear cell and macrophage, to remove killed virus by the activated lymphokine of killer cell activity.
3. in the infection hepatitis virus be, destroyed a large amount of hepatocyte, make the active attenuating of a lot of enzymes, thereby influenced hepatocellular biochemical function of detoxification.Alpha-linolenic acid participates in lipid metabolism in vivo, carbohydrate metabolism etc., increase the activity of multiple enzyme, recover the utilization of body to insulin, blood fat reducing and intrahepatic fat precipitation alleviate the hepatocyte burden, increase protein synthesis, stablize bile secretion, get rid of noxious substance, impel the resurrection of hepatocyte function.
6, aged effect is aging to be divided into the aging and physiological ageing of morbid state to alpha-linolenic acid to suppressing, but the two is difficult to tight separating.Senile dementia can be divided into two kinds on the unclear A Ercai Mohs type of thrombosis type and reason, and the former accounts for the overwhelming majority.Alpha-linolenic acid can suppress thrombotic disease, keep normal arterial pressure, suppress the cerebral hemorrhage morbidity, reduce the formation of cerebral thrombosis, improve the oxygen supply of brain cell, reduce the death of brain cell, the homergy of balance body, safeguard the function of each organ of body, reduce the generation of various diseases even cancer, improve intelligence, life-saving.Alpha-linolenic acid is the important composition composition of phospholipid, and phospholipid is the important structure composition of cell membrane.Along with the increase at age, the free radical that organism metabolism produces is attacked life macromolecule and is caused aging, and phospholipid can be repaired the biomembrane that is damaged again, and alpha-linolenic acid can also improve the activity of SOD in the human body, suppresses the generation of MDA, delays body aging.
7, alpha-linolenic acid is to suppressing the hemorrhagic cerebral apoplexy effect
Alpha-linolenic acid can participate in the synthetic of prostaglandin in human body, and the activity of raising prostaglandin, improve platelet economy and weaken platelet aggregation power, thereby effectively prevent hyperlipidemia, hypertensive generation, alpha-linolenic acid can be removed cholesterol superfluous in blood vessel and the surrounding tissue thereof, make it to transfer in the liver with discharging in the bile, reach antithrombotic, prevent and treat atherosclerosis and keep the unimpeded important function of blood flow.
8, alpha-linolenic acid is to suppressing the hemorrhagic cerebral apoplexy effect
Alpha-linolenic acid can participate in the synthetic of prostaglandin in human body, and the activity of raising prostaglandin, improve platelet economy and weaken platelet aggregation power, thereby effectively prevent hyperlipidemia, hypertensive generation, alpha-linolenic acid can be removed cholesterol superfluous in blood vessel and the surrounding tissue thereof, make it to transfer in the liver with discharging in the bile, reach antithrombotic, prevent and treat atherosclerosis and keep the unimpeded important function of blood flow.
The linolenic effect of r-:
Natural r-linolenic acid is present in the seed of Radix Oenotherae erythrosepalae and comfrey.
R-linolenic acid and arachidonic acid are named as vitaminF together, and vitaminF participates in important physical metabolic process in the body, is the precursor substance of prostaglandin, and prostaglandin lacks or deficiency in the body, can cause multiple disease.Initial prostaglandin is a kind of endocrine hormone of finding from prostata tissue, so called after prostaglandin, found afterwards that many organs such as lung, kidney, liver, intestinal etc. can both synthesize and secrete prostaglandin, and its physiologically active is more extensive, can relate to cardiovascular and cerebrovascular vessel, digestion and reproductive system, expansion periphery small artery is arranged, reduce vascular resistance, make the effect of blood pressure drops.And think and lack that endogenous blood vessel dilating material---prostaglandin is relevant in renal hypertension and the body.Next is an anticoagulant.
1986, China at first was used for the treatment of Radix Oenotherae erythrosepalae oil arteriosclerosis, hyperlipidemia and obesity.According to surveying and determination, the effect of r-linolenic acid cholesterol reducing is linoleic 163 times, is the most effective medicine of cholesterol reducing in the known now natural drug.
Do not contain the r-linolenic acid in the normal food.Increase gradually when the age, during diseases such as each organ aging of health or trouble hyperlipidemia, diabetes, coronary heart disease, dehydrogenase deficiency or active decline in the body then influence linoleic acid to be converted into vitaminF, cause the synthetic minimizing of prostaglandin.Because the prostaglandin deficiency, thereby easily suffer from diseases such as coronary heart disease, diabetes and hyperlipidemia.
Arachidonic acid.
Arachidonic acid (AA) and r-linolenic acid are class materials, and the r-linolenic acid is arachidonic precursor.WHO is with its common called after vitamin-F.
Arachidonic acid also is main essential fatty acid, and itself and lipoids metabolism have substantial connection, and is also very important to the metabolism of cholesterol.Cholesterol could turn round in vivo with after essential fatty acid combines, and carries out homergy.If shortage essential fatty acid, cholesterol will combine with some satisfied fatty acid, just can not normally transport metabolism in vivo, and may deposit in vivo, be further development of atherosclerosis, thereby cause hypertension, coronary heart disease, myocardial infarction, cerebrovascular disease etc.
General thought of the present invention is by the a-linolenic acid vascular peg stay plug to be dissolved, and by the r-linolenic acid solute is removed.Add arachidonic acid in the prescription and strengthened the linolenic function of r-.
Another characteristics of the present invention are the amounts that found the radical cure cardiovascular and cerebrovascular disease.The cardiovascular and cerebrovascular disease of clinical independent uses a-linolenic acid or r-linolenic acid treatment at present, every day general 1-3 milliliter, though there is certain curative effect can not dissolve and remove the interior established thromboembolism of blood vessel fast.
Our consumption that cardiovascular and cerebrovascular disease is heavily suffered from is that the said medicine combination is according to state of an illness 10-100 every day milliliter at present, be preferably 40-60 milliliter every day, the thromboembolism of blood vessel different parts could be effectively removed in only in this way continuously heavy dose of administration at short notice.In the past few years need the patients ' recovery treatment of bridging and lower carriage by 47 examples, medication every day is 50 milliliters in 15-45 days time, 43 examples that thrombosis is removed fully, and the 4 routine state of an illness also take a favorable turn in addition.
This drug regimen is to cerebral thrombosis, hypertension, and hyperlipidemia, the blood thickness, fatty liver, headache has high cure rate equally.Without any side effect, diarrhoea appears to this drug regimen in one or two people, can cooperate and take norfloxacin to human body.
Usage and consumption:
1, coronary heart disease, pulmonary heart disease, cerebral thrombosis is heavily suffered from 40-50 milliliter every day, takes night and morning, and takes 2-3 the course of treatment continuously course of treatment on the 15th, and cure rate can reach more than 85%.
2, hypertension takes the 20-30 milliliter and take night and morning every day, course of treatment on the 15th, takes 2-3 the course of treatment continuously, cure rate 90%.
3, blood thickness, the blood fat height is taken for 2 times 20 milliliters of every days sooner or later, and course of treatment on the 15th, 1 course cure rate is more than 95%.
Medicine of the present invention can be treated cardiovascular and cerebrovascular disease and hypertension effectively, does not recur after healing, effectively the life time limit of prolonged human.
The specific embodiment:
Embodiment 1, Fructus Perillae oil 89 grams, Radix Oenotherae erythrosepalae oil 10 grams and arachidonic acid 1 gram fully mix.
Embodiment 2, Fructus Perillae oil 87 grams, Radix Oenotherae erythrosepalae oil 12 grams, arachidonic acid 1 gram fully mix.
Embodiment 3, Fructus Perillae oil 84 grams, Radix Oenotherae erythrosepalae oil 14 grams, arachidonic acid 2 grams fully mix.
Embodiment 4, Fructus Perillae oil 80 grams, Radix Oenotherae erythrosepalae oil 17 grams, arachidonic acid 3 grams fully mix.
Claims (3)
1, a kind ofly can effect a radical cure cardiovascular and cerebrovascular disease and hypertensive medicine, it is characterized in that: adopt a-linolenic acid, r-linolenic acid and arachidonic acid to be mixed and made into, by weight calculating, the a-linolenic acid is 40-60; The r-linolenic acid is 0.6-1.4; Arachidonic acid is 0.2-1.2.
2, medicine according to claim 1 is characterized in that: the weight ratio of crude drug is 45-55 for the a-linolenic acid; The r-linolenic acid is 0.8-1.2; Arachidonic acid is 0.4-1.0.
3, medicine according to claim 1 and 2 is characterized in that: the weight ratio of crude drug is 50 for the a-linolenic acid; The r-linolenic acid is 1; Arachidonic acid is 0.4.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200910067571A CN101669930A (en) | 2009-09-18 | 2009-09-18 | Medicament capable of radically treating cardiovascular and cerebrovascular diseases and hypertensions |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200910067571A CN101669930A (en) | 2009-09-18 | 2009-09-18 | Medicament capable of radically treating cardiovascular and cerebrovascular diseases and hypertensions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101669930A true CN101669930A (en) | 2010-03-17 |
Family
ID=42017490
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200910067571A Pending CN101669930A (en) | 2009-09-18 | 2009-09-18 | Medicament capable of radically treating cardiovascular and cerebrovascular diseases and hypertensions |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101669930A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108741081A (en) * | 2018-06-29 | 2018-11-06 | 许昌元化生物科技有限公司 | One kind containing linolenic composite micro-powder and preparation method thereof |
| CN110755393A (en) * | 2019-12-01 | 2020-02-07 | 江苏黄河药业股份有限公司 | Lisinopril drop and preparation method thereof |
-
2009
- 2009-09-18 CN CN200910067571A patent/CN101669930A/en active Pending
Non-Patent Citations (3)
| Title |
|---|
| 于长青等: "花生四烯酸研究进展", 《农产品加工•学刊》 * |
| 王宏钊等: "α-亚麻酸药理研究进展", 《国际药学研究杂志》 * |
| 贾曼雪等: "γ-亚麻酸的生物学功能研究进展", 《国外医学（卫生学分册）》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108741081A (en) * | 2018-06-29 | 2018-11-06 | 许昌元化生物科技有限公司 | One kind containing linolenic composite micro-powder and preparation method thereof |
| CN110755393A (en) * | 2019-12-01 | 2020-02-07 | 江苏黄河药业股份有限公司 | Lisinopril drop and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102791263B (en) | For prevent or treat chronic venous insufficiency comprise VBT or the propionyl L-carmtme associating compositions as active component | |
| CN106890312A (en) | A kind of Elental suitable for liver cancer patient and preparation method thereof | |
| CN104644901A (en) | Chinese medicinal preparation for long-term prevention and treatment of cardiovascular and cerebrovascular diseases at remission stage and preparation method of Chinese medicinal preparation | |
| CN101669930A (en) | Medicament capable of radically treating cardiovascular and cerebrovascular diseases and hypertensions | |
| CN87106235A (en) | Treat atherosclerotic method and base composition | |
| Suo et al. | The effects of stimulation at acupoint ST36 points against hemorrhagic shock in dogs | |
| CN102113575A (en) | Perilla fruit blended edible vegetable oil enriched in essential fatty acids and vitamin F | |
| CN106729675A (en) | It is a kind of to treat pharmaceutical composition of cardiovascular and cerebrovascular disease and preparation method thereof | |
| CN101070338A (en) | Tanshinone IIA potassium sulfonate for preparing medicine for preventing and treating myocardial ischemia and cerebral ischemia and anoxia | |
| EP2445505B1 (en) | Combined use of creatine phosphate and creatine phosphokinase for treatment of arteriosclerosis | |
| WO2016015463A1 (en) | Uses of recombinant ganoderma lucidum immunoregulatory protein (rlz-8) in adjusting lipoprotein content in blood fat | |
| CN105287985A (en) | Application of composition to preparation of medicines for preventing and treating senile dementia | |
| CN101862318A (en) | Combined medicament-combined linolenic acid capable of preventing and fundamentally treating thromboembolic diseases | |
| Auerbach et al. | The iron revolution: Keeping abreast of the developments in iron therapy | |
| Colvin et al. | Parenteral Antiplatelet Agents in Three Patients Receiving VA-ECMO Support to Maintain Drug-Eluting Stent Patency | |
| CN104069173B (en) | Treat pharmaceutical composition of liver diseases and preparation method thereof | |
| JP2011505408A (en) | Method for using hydrogen fumarate and dihydrogen phosphate of 3- (2,2,2-trimethylhydrazinium) propionate in medicine | |
| CN102631370A (en) | Composition for preventing or improving hyperlipidemia and supplementing vitamin D | |
| CN101273776A (en) | Weikang soft capsules and producing process thereof | |
| Rubertsson et al. | Intra-aortic administration of epinephrine above aortic occlusion does not alter outcome of experimental cardiopulmonary resuscitation | |
| Jung et al. | Reviewing the studies of the National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome Network: outcomes and clinical findings | |
| Powell et al. | Bedside VA-ECMO Cannulation for a Patient with CTEPH and RV Failure | |
| CN1857293A (en) | Medicine composition containing wild astragaloside and paeoniforin | |
| Kipshidze et al. | New Approaches to Treatment of Gerontologic Patients with the Presence of Ischemic Heart Disease (IHD) with Syndrome of Stenocardia | |
| JP2008308499A (en) | Combined drug for attaining three principles of non-illness, health and vitality to maintain life up to 100 years old |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20100317 |